Now that the federal government is finally taking action on cannabis rescheduling — moving it to Schedule III and creating de facto medical cannabis legalization — many are wondering about the status of cannabis stocks as a whole. Cannabis stocks, as a whole, spiked upwards on the news but quickly reverted to pre-announcement norms. That’s because creating a medical mandate for cannabis may prove more disruptive to the status quo than expected (and not in a good way) — but the uncertainty created is proving too much for most investors to stake their cash on any specific cannabis stock today.
One industry expert, Jordan Tritt, founder and CEO of The Panther Group, told me via email that he expects “medical cannabis to be a part of the overall existing medical supply chain” and that “this will be advantageous to endemic players.” At the same time, recreational sellers could benefit long-term, too, since they “will ultimately function like liquor stores and dispense more concentrated, non-medical, dosed cannabis products.”
With that in mind, these three cannabis stocks to buy represent the best blend of entrenched medical cannabis operations while picking the “best in class” recreational retailers to capture that side of the
